{
    "nct_id": "NCT04743934",
    "official_title": "RAD 2003/XUAB2104: Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer",
    "inclusion_criteria": "* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Ability to take oral medication and be willing to adhere to the study regimen.\n* Male age >18 years.\n* Histologically confirmed prostate cancer.\n* Currently receiving gonadotropin releasing hormone agonist/antagonist monotherapy.\n* Serum testosterone <50 ng/dL.\n* Serum AST and ALT less than 2 times upper limit of normal.\n* Endorsed reduced sexual interest.\n* Attempted intercourse.\n* Current sexual partner.\n* Was sexually active with partner within 6 months prior to ADT.\n* No other antineoplastic therapy planned during study period.\n* No active symptoms attributable to systemic prostate cancer.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current systemic prostate cancer treatment besides GnRH agonist/antagonist, anti-androgens, or abiraterone.\n* Prior to ADT had erections not firm enough for intercourse despite use of pharmacologic agents such as phosphodiesterase-5 inhibitors.\n* Current symptoms attributable to active prostate cancer\n* Moderate or heavy alcohol use (>2 drinks/day)\n* Concurrent moderate or strong CYP3A4 inhibitors\n* Concurrently taking medication classified as a monoamine oxidase inhibitor.",
    "miscellaneous_criteria": ""
}